Anavex Life Sciences
Pre-Approval PRO BETA 🔴
Stale Activity
No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 3/15/2024
11
Total Trials
4
Phase 3
9
Phase 2
1
Recruiting
135
Score
Pipeline by Phase
Phase 3
4
Phase 2
9
Phase 1
1
Therapeutic Focus
Rett Syndrome Alzheimer Disease Alzheimer's Disease Schizophrenia Parkinson Disease Dementia
Clinical Trials (11)
A Study of ANAVEX3-71 in Adults With Schizophrenia
Started: 3/15/2024
ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome
Started: 7/1/2020
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
Started: 10/10/2019
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Started: 7/3/2018
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Started: 3/1/2016
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
Started: 12/1/2014
Drug Candidates
ANAVEX3-71 oral capsules Placebo oral capsules ANAVEX2-73 ANAVEX2-73 oral liquid Placebo oral liquid High dose ANAVEX2-73 Mid dose ANAVEX2-73 Placebo oral capsule Placebo ANAVEX3-71
Activity Status:
Stale
Last Trial Started: 3/15/2024
Last Trial Ended: 6/14/2024
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.